Related Experiment Video
Updated: Oct 1, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease
Morgan E Belina1, Timothy A Driscoll2, Sarah K Blanchard3
1Duke University School of Medicine, Durham, North Carolina, USA.
Abstract:
Chronic graft-versus-host disease (cGVHD) of the skin is a serious cause of long-term morbidity and mortality among patients who receive hematopoietic stem cell transplants. Systemic corticosteroids remain first-line treatment for cutaneous cGVHD; however, there is currently no consensus on second-line therapy for steroid-refractory disease. We herein present a case of a pediatric patient with severe cGVHD of the skin, nonresponsive to corticosteroids, who was successfully treated with a prolonged course of ruxolitinib with minimal side effects.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Continuous Renal Replacement Therapy

